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Background/aim: In this experimental study, we aimed to evaluate the late period effects of the combination of Ankaferd Blood
Stopper (ABS), which has bone wound healing effects, and β-tricalcium phosphate (TCP) on the regeneration of bone tissue through
histopathological, immunohistochemical, and radiological (dual energy X-ray absorptiometry - DEXA) methods in nondiabetic rats.
Materials and methods: Sixty-four Wistar albino male rats were used. In the calvaria of the rats, a bone defect 7.0 mm in diameter was
created. These rats were divided into 4 different groups. Group 1 was the control group without any treatment, a 0.125 mL Β-TCP graft
was applied to Group 2, a 0.125 mL ABS was applied to Group 3, and a 0.125 mL (β-TCP + ABS) mixture was applied to group 4. Half
of the rats were sacrificed on day 28 and the other half on day 56. Histopathological, immunohistochemical, and DEXA analyses of the
specimens were performed after the experiment.
Results: As a result of the histopathological analysis, osteoblastic activity and new bone formation were found to be significantly higher
in Group 2, Group 3, and Group 4 than the control group on day 28 (P < 0.05). However, inflammatory cell infiltration and vascular
dilatation and hemorrhage decreased significantly compared to the control group (P < 0.05). The histopathological analysis in rats on
day 56 showed that osteoblastic activity in Group 2 and Group 4 was significantly higher than in the control group, but there was a
statistically significant decrease in inflammatory cell infiltration and vascular dilatation and hemorrhage compared to the control group
(P < 0.05). New bone formation in Group 2, Group 3, and Group 4 was significantly higher than in the control group. Western blotting
findings revealed that the osteonectin and osteopontin expression on day 28 was increased significantly in Group 2 and Group 4. DEXA
analyses revealed that BMC values in Group 2 and Group 4 on day 28 were significantly higher than in the control group (P < 0.05).
There was no significant difference in bone mineral density values on the 28th and 56th days (P > 0.05).
Conclusion: The use of both β-TCP + ABS and only ABS had positive effects on wound healing and bone formation in nondiabetic rats.
Key words: Ankaferd Blood Stopper, bone regeneration, alloplastic graft, dual energy X-ray absorptiometry

1. Introduction
Periodontal disease is an infectious disease with a complex
pathogenesis characterized by periodontal tissue and bone
loss, in which local factors, host response, environmental
factors, and genetic predisposition play important roles
in etiology (1). The inflammation occurring during
the development of a periodontal disease may result in
degeneration of bone tissue causing changes in bone
morphology (2). However, in periodontal defects,

various graft materials are used to remove deformities
caused by tooth extraction and trauma. The aim of the
bone regeneration process is to increase the volume of
bone (3). In order to achieve the desired success in these
applications, experimental and clinical studies are still
being carried out. However, despite these studies, there is
not yet an ideal graft material that will allow the lost tissues
to be recovered and the bone defects to be filled completely.
Studies have focused on bone structure, types of bone
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graft materials, and factors affecting bone metabolism and
aimed at accelerating bone regeneration (3,4).
Several biomaterial graft materials are needed for
bone regeneration. Today, autogenic, allogenic, and
alloplastic bone grafts are used for this purpose. The
rapid and predictable regeneration capacity of bone grafts
in large bone defects is limited. This is due to the fact
that biologically active molecules, bone morphogenesis
proteins, and other growth factors are not sufficiently
present to replace the bone and provide bone formation
in bone grafts (5,6). Autogenous graft materials require
a second operation at the donor site, allowing long-term
pain, limitation of movement, and a long maintenance
period, thus limiting the use of this graft type (7). Betatricalcium phosphate (β-TCP), one of the most popular
synthetic grafts in recent years, is a safe biocomposite graft
material with osteoconductive bioactive properties. β-TCP
is partially resorbed, holding the bone mechanically
and allowing the replacement of the bone with graft as a
biological filler. However, it is a weak bone graft due to
improper porosity, having a small grain and dissolving in a
period of 6 weeks (4,8).
Ankaferd Blood Stopper (ABS; Ankaferd Medication
Cosmetics A.S., İstanbul, Turkey) is an important plant
extract in Turkish medicine used as an antihemorrhagic
agent, consisting of Glycyrrhiza glabra, Vitis vinifera, and
Alpinia officinarum dried leaf extracts and dried root
extracts of Urtica dioica and Thymus vulgaris (9). ABS
creates a protein network by forming the aggregation of
other protein molecules, especially fibrinogen, in areas
where tissue integrity is disrupted. In the formation of
this protein network, erythrocytes, thrombocytes, and
red blood cells are effective and in particular erythrocyte
aggregation occurs in this network. This occurs as a purely
physiological process in which no coagulation factor is
affected in the hemostatic process (10). In addition, it has
been reported that ABS has a beneficial effect on early bone
healing (11). As a second feature, ABS has been reported
to have antiinflammatory and antioxidant effects. Its late
effects on bone have not been determined conclusively
(12).
We did not find any study in the literature suggesting
the effect of ABS on the late period recovery of bone
tissue. The aim of this study was to investigate the effects
of combined use of β-TCP, a graft material, and ABS,
known as an antihemorrhagic, on bone regeneration by
using histological, immunohistochemical, western blot,
and radiological methods.
2. Materials and methods
The experimental animals local ethics committee of Dicle
University approved this study with a protocol number
of 2015/13. Operations on experimental animals were

conducted in the operating room of the Dicle University
Medical Sciences Research and Application Center, the
histological and immunohistochemical experiments in
the laboratories of the Dicle University Medical Faculty
Department of Histology and Embryology, and the
radiological examinations in the laboratories of the Dicle
University Medical Faculty Department of Biophysics.
Sixty-four 4-month-old Wistar male albino rats with an
average weight of 300 g were used. Experimental animals
were maintained in a cycle of 12 h of light and 12 h of dark.
The rats were provided free access to water and food (ad
libitum) and the room temperature was kept constant at
22 ± 2 °C.
2.1. Surgical method
Experimental animals were fasted 12 h before surgery.
Injection anesthesia was applied to the rats with ketamine
HCl 10% (Ketasol, Ricter Pharma, Welsh, Austria) and 3
mg/kg xylazine HCl 2% (Xylazinbio, Bioveta, Intermed
Medicine Depot, Ankara, Turkey). The eyelid reflex was
expected to disappear for proper anesthesia depth, and
the operation area from the neck to the forehead was
shaved and painted with 10% povidone-iodine antiseptic
solution (Betakon, Aroma, Tekirdağ, Turkey). An incision
was made in the coronal midline of the head’s skin with
a No. 15 stainless steel surgical scalpel, the heads were in
a free position, and then the frontal bones were revealed
with periosteal elevator. After that operation, with the
aid of a 7.0-mm trephine mill (Trephine, SC Medical
Products Industry and Trade Co., İzmir, Turkey), a full
layer of bone incision was performed in the midline in a
circular pattern. Care was taken to protect the dura mater
and superior sagittal sinus during the operation. Separate
applications were performed for 7.0-mm-diameter defects
of each experimental group. The postoperative skin
incision was primarily closed with 3/0 silk suture (Silk,
Jinhuan Medical Products Ltd., China). For purposes of
prophylaxis, immediately after the operation, a single
dose of 50 mg/kg antibiotic (Betamoxla, Active, İstanbul,
Turkey) was injected into the right gluteal muscle of each
rat one time.
2.2. Groupings of experimental animals in the study
Nondiabetic rats used in our study were used for 2 different
periods, as the 28th day and 56th day. In these two periods,
4 different subgroups were created:
Group 1: No procedure was performed to the bone
defects of 16 rats; the defects were left empty and the skin
incisions were closed. Eight of the rats were sacrificed on
the 28th day and the remaining 8 on the 56th day.
Group 2: A 0.125 mL β-TCP graft with 0.25–1 mm
particles was inserted into the defects of 16 rats. Eight of
the rats were sacrificed on day 28 and the remaining 8 on
day 56.
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Group 3: 0.125 mL of ABS was applied to the defects of
16 rats. Eight of the rats were sacrificed on day 28 and the
remaining 8 on day 56.
Group 4: 0.125 mL of β-TCP graft + ABS was applied to
the bone defects of 16 rats. Eight of the rats were sacrificed
on day 28 and the remaining 8 on day 56.
In experimental animals, euthanasia was performed
on 32 rats on day 28 and the other 32 rats on day 56. Rats
were anesthetized with 45 mg/kg ketamine HCl 10%, then
sodium thiopental (Pentalyn Sodyum, Ulagay, İstanbul,
Turkey), for which the lethal dose of 60 mg/kg was injected.
2.3. Preparation of sections for histological evaluation
After the rats were euthanized, the calvarial bone was
removed in a circular way with round dental bur to
cover the defect area. The samples were placed in 10%
formaldehyde solution, then directly fixed in a neutral
buffered formalin solution in the histology laboratory.
After the complete fixation of the samples, they were
washed for 12 h under water, then were suspended in
gradually concentrated alcohol for dehydration (30%,
50%, 70%, 80%, 90%, 96%, and 100%) for 12 h. After a
transparency process in xylol, infiltration of the tissues
was immediately done and they were buried in paraffin
blocks. After sectioning with a microtome (RM 2265
Rotatory Microtome, Leica, Germany), paraffin blocks
with a thickness of 5 µm were stained with hematoxylin
and eosin (H&E) for routine staining. In this study, the
osteoblastic activity, inflammatory cell infiltration, vessel
dilatation and hemorrhage, and new bone formation
parameters were histopathologically evaluated.
2.4. Preparation of sections for immunohistochemical
evaluation
Sections of paraffin blocks of 5 µm were placed on
poly-L-lysine-coated slides and then were held at room
temperature. They were kept in a 60 °C incubator for
1 night. After the sections cooled, they were kept in the
xylenes for 2 to 5 min, followed by a 96%, 80%, 70%, and
60% ethyl alcohol for 5 min. After passing through alcohol
concentrations, they were kept in distilled water for 5 min.
Then they were put into EDTA solution to dissolve the
bone tissue. The samples taken on slides were surrounded
by Dako Pen (Huiyou, China). In a 700 W microwave
oven, they were kept in citric acid (pH 6.0) for 7 + 5 min
to remove the antigen masking. They were then cooled
for 20 min at room temperature, washed with phosphatebuffered saline (PBS) solution for 3 × 5 min, and kept in
3% hydrogen peroxide (H2O2) to provide endogenous
peroxide blockade for 20 min. The sections were again
kept in PBS for 3 × 5 min and taken into the incubation
container. All subsequent operations were carried out in
this incubation container. Block solution (Histostain-Plus
Kit, Invitrogen, Carlsbad, CA, USA) was dripped and
kept for 1 h, and then osteonectin (mouse monoclonal,
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1/2200, Santa Cruz Biotechnology, Santa Cruz, CA, USA)
and osteopontin (mouse monoclonal, 1/200, Santa Cruz
Biotechnology) antibodies were applied to the sections.
The primary antibody was dropped and kept for 1 h, then
washed with PBS solution for 3 × 5 min. After dropping
the biotinized secondary antibody (Histostain-Plus Kit,
Invitrogen) compatible with the primary antibody, it
was kept in a closed moist box at room temperature for
30 min. Immediately after washing with PBS solution for
3 × 5 min, the secondary antibody (Zymed, HistostainPlus Kit, Invitrogen) marked with streptavidin was
dripped and waited for 30 min at room temperature in
the closed moist box, then washed with PBS solution
for 3 × 5 min. Aminoethyl carbazole was dripped as a
chromogen, then washed with distilled water to prevent
the reaction of antigen/antibody. Contrast staining with
Mayer’s hematoxylin was done, and the sample was again
distilled with water and closed with a cover slide. In
the final stage, the sections were evaluated and viewed
immunohistopathologically with a photomicroscope
(Nikon Eclipse i50, Tokyo, Japan) for blind evaluation.
2.5. Western blotting method
2.5.1. Cell lysis and protein quantitation
The calvarial tissues frozen in liquid nitrogen were
powdered in a porcelain mortar, while 50 mg of powdered
placenta tissue was kept in 250 µL of RIPA lysis solution
containing a mixture of protease inhibitor in ice for 1 h.
Lysed placenta samples were stored at –86 °C. All the steps
were taken on ice to prevent protein degradation. Total
cellular protein concentration was calculated using the
BCA Kit (Pierce, Thermo Scientific, Waltham, MA, USA).
The BCA measurement was made in 96-well plates with a
microplate reader (Multiscan Go, Thermo Scientific).
2.5.2. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
Protein samples were prepared in 1X SDS loading solution
(2% SDS, 5% glycerol, 0.01% bromophenol blue, 8% DLdithiothreitol (DTT), then boiled at 95 °C for 5 min.
Next, 20 µg of protein samples were loaded onto 10%
polyacrylamide gel, and electrophoresis was performed
in SDS running solution (2.4 mm Tris, 19.2 mm glycine,
0.01% SDS) for 1 h at 200 V.
2.5.3. Membrane transfer and antibody staining of proteins
Separated proteins were transferred from SDS-PAGE to
PVDF membrane in transfer solution at 100 V for 1 h. After
transfer, the membrane was blocked at room temperature
for 1 h in 5% milk powder prepared in PBS-T solution.
After the blockage process, the membrane was treated
at room temperature for 2 h with primary antibodies
and the membrane was washed 4 times with PBS-T for
30 min. After washing, the membrane were treated with
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horseradish peroxidase-conjugated secondary antibodies
at room temperature for 1 h at 1:10,000 dilution rate. The
membrane was washed again 4 times with PBS-T for 30
min. Protein bands were visualized using the enhanced
chemiluminescent reagent chemical (Bio-Rad, Hercules,
CA, USA). Photos were taken using the ChemiDoc MP
(Bio-Rad) device.
2.6. Radiological evaluation
Bone defect measurements of rats were taken by dual
energy X-ray absorptiometry (DEXA). Bone mineral
density (BMD) measurements of all rats were made with the
QD 450 ACCLAIM SERIES ELIENTE HOLOGIC DEXA
(Hologic, Bedford, MA, USA) device, but only the BMD
of the head was evaluated. After all rats were anesthetized
with injections, the DEXA tool was withdrawn before
starting and being stored. Measurements were obtained as
bone mineral content (BMC) in grams and bone mineral
density (BMD) values in g/cm2.
2.7. Statistical analysis
Statistical analysis of the data obtained in our study was
realized using SPSS 21.0 Windows (IBM Corp., Armonk,
NY, USA). Radiological and histological data are shown as
numerical values, mean (M), and standard deviation (SD).
The Mann–Whitney U test was used to compare the data
with nonnormal distributions for binary comparisons,
and the Kruskal–Wallis test was used to compare multiple
comparisons. The Bonferroni corrected Mann–Whitney
U test was performed in comparisons of multiple groups.
The Wilcoxon test was used for in-group comparisons. P <
0.05 was accepted as significant in all statistical tests.
3. Results
Experimental animals were in cages provided with
appropriate environmental conditions after surgery until
the 28th and 56th days of healing periods.
3.1. Histological results
As a result of the H&E staining procedure (Figures 1A–
1H), the following results were obtained. In Group 1,
histological analysis on day 28 revealed that inflammatory
cells around the vessel in the defect region were observed
clearly, fibrous tissue was increased, and bone trabeculae
and osteoblastic cells became apparent (Figure 1A). In the
histopathological analysis of Group 1 performed on day
56, bone trabeculae in the form of small islets and collagen
fiber increase with fibrous tissue began to appear (Figure
1E).
On histopathological evaluation in Group 2 on day
28, we observed that cellular infiltration intensified and
vascular hemorrhages decreased. The osteoclastic activity
also decreased and osteoblast cells were activated, and
osteocytes became apparent in lacunar structures and
bone trabeculae. Small islet bone marrow fragments
were observed in the middle parts of the enlarged bone

trabeculae (Figure 1B). On histopathological evaluation at
day 56 in group 2, a significant increase in collagen fibers
and connective tissue cells and an increase in osteoblast
activity were found, and osteocytes were seen in the
lacunae. Bone trabeculae were observed to enlarge for new
bone formation (Figure 1F).
In Group 3, histopathological evaluation on day
28 showed that bone trabeculae became apparent, and
osteoblastic activity and osteocyte formation developed.
Cellular activity of collagen fiber development in connective
tissue increased (Figure 1C). On histopathological
evaluation in Group 3 on day 56, dilatation and freespreading erythrocytes in blood vessels, a partial reduction
in inflammatory cells, increased osteoblastic activity, and
osteocytes beginning to form new bone precursors and
bone trabeculae as small pieces were all observed (Figure
1G).
On histopathological evaluation in Group 4 on day 28,
bone trabeculae had matured and bone marrow became
apparent. The formation of new bone was observed.
Collagen fibers and connective tissue cellular increase
occurred (Figure 1D). On histopathological evaluation
in Group 4 on day 56, bone trabeculae displaying the
formation of new bone began to enlarge, enabling the
creation of bone cells among them. Osteoblastic activity
and osteocyte formation enlarged by spreading the graft
area (Figure 1H).
3.2. Immunohistochemical results
As a result of the osteopontin immune staining procedure
(Figures 2A–2H), the following results were obtained. In
Group 1, osteopontin staining at day 28 showed positive
osteopontin expression in osteoblasts present in small
bone fragments (Figure 2A). Immunohistochemical
analysis of osteopontin staining in Group 1 on day 56
revealed positive osteopontin expression in osteoblastic
cells around bone trabeculae together with an increase in
connective tissue outside the graft site (Figure 2E).
In the immunohistochemical analysis performed
in Group 2 on day 28, osteoblast expression was
positive (Figure 2B) in osteoblast cells in the enlarged
bone trabeculae between the grafts. In group 2,
immunohistochemical analysis at day 56 showed that the
number of bone trabeculae increased, and osteoblast cells
showed obvious osteopontin expression and osteocyte
cells occurred (Figure 2F).
In Group 3, we found that an increase in osteoblastic
activity and osteopontin-positive reaction were
determined in osteoblast cells in the immunohistochemical
analysis performed at day 28 (Figure 2C). In Group 3,
the immunohistochemical analysis performed at day 56
showed positive osteopontin expression in osteoblast cells
other than bone trabeculae in different shapes within the
graft area (Figure 2G).
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Figure 1. A) The inflammatory cells in the histopathological section taken from Group 1 on day 28 are shown with a thick white arrow.
B) In the histopathological section taken from Group 2 on day 28, the lacunar structures of the osteocyte cells are shown with a thin
black arrow, and the bone marrow sections are shown with a thick white arrow. C) Osteoblastic activity and osteocyte formation in
histopathological section taken from Group 3 on day 28 are shown with a thick white arrow. D) Bone marrow in the histopathologic
section taken from Group 4 on day 28 shown with a star. E) A histopathologic section taken from Group 1 on day 56; collagen fibers and
fibrous tissue are shown with a thin black arrow, and islet-shaped bone trabeculae are shown with a thick white arrow. F) A histopathologic
section taken from Group 2 on day 56; osteocytes are shown with a thick white arrow. G) A histopathologic section taken from group
3 on day 56; erythrocyte cells are shown with thin black arrow and bone trabeculae pieces with stars. H) Histopathologic section taken
from Group 4 on day 56; bone trabeculae enlarge to form bone marrow, and osteocytes spread to the graft site. Hematoxylin and eosin
staining; bar = 100 µm.

Immunohistochemical analysis in Group 4 at day 28
showed an increase in osteopontin expression in osteoblast
cells in enlarged bone trabeculae between the graft areas
(Figure 2D). On day 56, the new bone structure was fully
formed, and positive osteopontin expression occurred in
the osteoblast cells, matrix area, graft area, and outside the
large bone trabeculae (Figure 2H).
As a result of the osteonectin immunostaining
procedure (Figures 3A–3H), the following results were
obtained. According to the results of osteonectin staining
in Group 1 on day 28, its expressions were observed
positive in some precursor connective tissue cells other
than graft sites (Figure 3A). The analysis of osteonectin
staining in Group 1 on day 56 revealed negative osteonectin
expression in small bone trabeculae outside the graft sites
(Figure 3E).
Immunohistochemical analysis at day 28 in Group 2
revealed osteonectin-positive expressions in osteocytes
in the trabeculae enlarging between the graft fragments
(Figure 3B). In Group 2, analysis at day 56 showed that
bone trabeculae began to develop within the graft site,
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and the expression was positive in osteocytes of bone
trabeculae (Figure 3F).
In Group 3 at day 28, osteonectin expression was
observed in a small number of osteocyte cells among small
bone trabeculae formed within the graft area (Figure 3c).
In Group 3, the immunohistochemical analysis performed
on day 56 showed osteonectin-positive expression in a
small number of osteocyte cells and the prominence of
bone matrix in long bone trabecula (Figure 3G).
In the analysis performed on the 28th day in Group
4, osteocyte cells showed positive osteonectin expression
in bone trabeculae that tended to be unified with graft
fragments (Figure 3D). Immunohistochemical analysis
at day 56 of Group 4 revealed that bone trabeculae were
enlarged in the graft site and osteonectin expression was
positive in osteocytes (Figure 3H).
3. 3. Western blotting results for osteonectin and osteopontin expression
The expression level of osteonectin in the calvarial tissue
increased dramatically in the β-TCP and ABS + β-TCP
groups on day 28 (Figure 4). Total protein (20 µg) was
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Figure 2. A) Positive osteopontin expression in osteoblasts in immunohistochemical section taken from Group 1 on day 28 (yellow
arrow). B) The osteopontin expression was positive in bone trabecula in the immunohistochemical section taken from Group 2 on
day 28 (yellow arrow). C) There was an osteoblastic increase (red arrow) and positive expression of osteopontin (yellow arrow) in
immunohistochemical section taken from Group 3 on day 28. D) The immunohistochemical section from Group 4 on day 28; there
was an increase of osteopontin expression in osteoblast cells (yellow arrow). E) An immunohistochemical section taken from Group
1 on day 56; there was an increase of osteopontin expression in osteoblast cells (thin black arrow). F) An immunohistochemical
section taken at 56th day from Group 2; there was a marked increase of osteopontin expression in osteoblast cells (yellow arrow). G)
Immunohistochemical section taken at 56th day from Group 3; there was a positive increase in osteopontin expression in osteoblast
cells (yellow arrow). H) Immunohistochemical section taken at 56th day from group 4; there was a positive increase in osteopontin
expression in osteoblast cells (yellow arrow). Osteopontin immunostaining; bar = 100 µm.

run on a gel. Antiosteonectin and anti-β-actin antibodies
were used in western blotting. β-Actin was used for load
control.
The level of osteopontin expression in calvarial tissue
had increased dramatically in the β-TCP and ABS + β-TCP
groups on day 28 (Figure 5). Total protein (20 µg) was run
on a gel. Antiosteonectin and anti-β-actin antibodies were
used in western blotting. β-Actin was used for load control.
3.4. Statistical results
3.4.1. Histopathological statistics
For the results of the histopathological examination of
the bone samples taken the calvaria of the nondiabetic
rats on the 28th and 56th days, the values of osteoblastic
activity, inflammatory cell infiltration, vascular dilation
and hemorrhage, and new bone formation were compared
between all groups by Kruskal–Wallis test and a statistically
significant difference was found between all groups (Table
1) (P < 0.001).
The Mann–Whitney U test with Bonferroni correction
was performed on the 28th day for nondiabetic rats’
data that were also significant by Kruskal–Wallis test.

Osteoblastic activity, inflammatory cell infiltration, and
new bone formation scores were compared between
groups; there was a significant difference between the
control group and the other groups. In comparison of
vascular dilatation and hemorrhage scores between
groups, significant differences were found between Groups
1 and 2, 1 and 3, 1 and 4, 2 and 3, and 3 and 4 (Table 1).
The Mann–Whitney U test with Bonferroni correction
was also performed for nondiabetic rats’ 56th day data that
were also significant by Kruskal–Wallis test. Comparison
of osteoblastic activity scores between groups was
conducted. Significant differences were found between
Groups 1 and 2, 1 and 4, 2 and 3, 2 and 4, and 3 and 4.
There was a significant difference between Group 1 and
Group 2, Group 1 and Group 3, and Group 3 and Group
4 in the comparison of inflammatory cell infiltration and
vessel dilatation and hemorrhagic scores between groups.
According to the comparison of new bone formation
scores between groups, there was a significant difference
between Groups 1 and 2, 1 and 3, 1 and 4, 2 and 3, and 3
and 4 (Table 1).
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Figure 3. A) Immunohistochemical sections taken from Group 1 on day 28; osteonectin expression in connective tissue cells was
positive (yellow arrow). B) Immunohistochemical section from Group 2 on day 28; osteonectin expression in osteocytes was positive
(yellow arrow). C) Immunohistochemical section taken from Group 3 on day 28; osteonectin expression in osteocytes was positive
(yellow arrow). D) Immunohistochemical section taken from Group 4 on day 28 shows positive osteonectin expression in osteocytes
(thin black arrow). E) Immunohistochemical section taken from Group 1 on day 56 shows negative osteonectin expression in osteocytes
(yellow arrow). F) Immunohistochemical section taken at 56th day from Group 2 shows positive osteonectin expression in osteocytes
(yellow arrow). G) Immunohistochemical section taken at 56th day from Group 3 shows positive osteonectin expression in osteocytes
(black arrow). H) Immunohistochemical section taken at 56th day from Group 4 shows positive osteonectin expression in osteocytes
(yellow arrow). Osteonectin immunostaining; bar = 100 µm.

Figure 4. Osteonectin expression in calvarial tissue increased significantly in β-TCP and ABS + β-TCP groups at day 28.

3.4.2. DEXA results
The Kruskal–Wallis test was used to compare mean BMC
and BMD data in the calvarial bone defects of diabetic
rats. According to this test, BMC and BMD were found to
be statistically insignificant between the groups, and the
BMC values of days 28 and 56 were found to be statistically
significant (Table 2).
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The Mann–Whitney U test with Bonferroni correction
was applied to nondiabetic rats’ 28th day data that were
significant by Kruskal–Wallis test. According to the
comparison of BMC values between

groups, a significant
difference was found between Groups 1 and 2, 1 and 4, 2
and 3, and 3 and 4. According to the comparison of BMC
values between groups of 58-day-old rats, a significant
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Figure 5. Osteopontin expression in calvarial tissue increased significantly in β-TCP and ABS + β-TCP groups on day 28.

Table 1. Comparison of histopathological values of nondiabetic rats at 28th and 56th days.

56th day 28th day 56th day 28th day 56th day 28th day 56th day 28th day

New bone
formation

Vessel dilatation
and hemorrhage

Inflammatory cell
infiltration

Osteoblastic
activity

Groups

Group 1
Group 2
(mean ± SD) (mean ± SD)

Group 3
Group 4
P
(mean ± SD) (mean ± SD)

1.38 ± 0.52

2.38 ± 0.74

2.50 ± 0.54

3.00 ± 0.54

1.75 ± 0.46

2.87 ± 0.35

2.00 ± 0.54

3.00 ± 0.54

1.50 ± 0.53

2.50 ± 0.54

P1-2

P1-3

P1-4

P2-3

P2-4

P3-4

˂0.001** 0.014*

0.003*

0.001**

0.814

0.077

0.085

3.62 ± 0.52

˂0.001** 0.001**

0.332

˂0.001** 0.004*

0.008*

0.001**

2.00 ± 0.54

1.00 ± 0.54

˂0.001** 0.001**

0.004*

˂0.001** 0.085

0.085

0.004*

1.25 ± 0.46

2.50 ± 0.54

0.75 ± 0.46

˂0.001** 0.002*

0.694

˂0.001** 0.002*

0.053

˂0.001**

2.50 ± 0.54

1.00 ± 0.54

1.63 ± 0.52

1.00 ± 0.54

˂0.001** 0.001**

0.010** 0.001**

0.036*

0.525

0.036*

2.50 ± 0.54

1.38 ± 0.52

2.87 ± 0.35

1.00 ± 0.54

˂0.001** 0.003*

0.117

0.001**

0.001**

0.175

˂0.001**

1.38 ± 0.52

3.00 ± 0.54

2.63 ± 0.52

3.00 ± 0.54

˂0.001** 0.001**

0.002*

0.001**

0.175

0.248

0.175

1.25 ± 0.46

3.25 ± 0.46

1.88 ± 0.35

3.50 ± 0.54

˂0.001** ˂0.001**

0.015*

˂0.001** ˂0.001** 0.317

˂0.001**

*: Significant difference between groups at P ≤ 0.005.
**: Significant difference between groups at P ≤ 0.001.
P, Kruskal–Wallis test; P1-2, P1-3, P1-4, P2-3, P2-4 and P3-4, Mann–Whitney U test.

difference was found between Group 2 and 3, and Groups
3 and 4 (Table 2).
In-group comparisons of bone defects in calvaria of
nondiabetic rats revealed no significant difference in the

comparison of BMC and BMD values up to the 28th day
and 56th day. In the comparison of the groups for bone
defects in the calvaria of nondiabetic rats, a significant
difference was found in the comparison of BMC values of
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the 28th and 56th days in all groups. There was a significant
difference in BMD values between groups at the 28th day
and the 56th day in Groups 2 and 4 (Table 3).
4. Discussion
The strength and continuity of bone tissue can be impaired
for different reasons. Bone loss can occur in patients with

periodontal diseases, acute and chronic pathological
processes, cysts, and trauma. Small bone defects can heal
spontaneously without any surgical intervention, but large
bone defects require reconstructive surgery. The success
of bone regeneration depends on defect morphology and
graft material. The applicability of regenerative procedures
is limited and it is still difficult to obtain the desired new

Group 1
(mean ± SD)

Group 2
(mean ± SD)

Group 3
(mean ± SD)

Group 4
(mean ± SD)

P

P1-2

P1-3

P1-4

P2-3

P2-4

P3-4

Beginning

2.34 ± 0.21

2.25 ± 0.10

2.25 ± 0.11

2.26 ± 0.11

0.904

-

-

-

-

-

-

28th day

2.44 ± 0.11

2.76 ± 0.20

2.55 ± 0.03

2.73 ± 0.09

0.005* 0.014* 0.110

0.014* 0.020* 0.769

0.021*

56th day

2.88 ± 0.12

3.03 ± 0.07

2.81 ± 0.17

3.10 ± 0.16

0.040* 0.050

0.539

0.065

0.043* 0.663

0.043*

Beginning

0.31 ± 0.01

0.30 ± 0.01

0.31 ± 0.01

0.30 ± 0.02

0.669

-

-

-

-

-

-

28th day

0.31 ± 0.11

0.32 ± 0.01

0.31 ± 0.01

0.31 ± 0.01

0.074

-

-

-

-

-

-

0.33 ± 0.01

0.34 ± 0.01

0.33 ± 0.02

0.35 ± 0.02

0.076

-

-

-

-

-

-

56th day

BMD

BMC

Table 2. Comparison of BMC and BMD values between groups of nondiabetic rats.

*: P ˂ 0.05, significant difference between groups.
P, Kruskal–Wallis test; P1-2, P1-3, P1-4, P2-3, P2-4, and P3-4, Mann–Whitney U test.
Table 3. In-group comparisons of BMC and BMD values of nondiabetic rats.
Beginning

28th day

56th day

P0-28

P0-56

P28-56

Group 1
(mean ± SD)

BMC

2.34 ± 0.21

2.44 ± 0.11

2.88 ± 0.12

0.345

0.068

0.009*

BMD

0.31 ± 0.01

0.31 ± 0.11

0.33 ± 0.01

0.655

0.059

0.166

Group 2
(mean ± SD)

BMC

2.25 ± 0.10

2.76 ± 0.20

3.03 ± 0.07

0.066

0.068

0.042*

BMD

0.30 ± 0.01

0.32 ± 0.01

0.34 ± 0.01

0.066

0.066

0.015*

Group 3
(mean ± SD)

BMC

2.25 ± 0.11

2.55 ± 0.03

2.81 ± 0.17

0.068

0.068

0.043*

BMD

0.31 ± 0.01

0.31 ± 0.01

0.33 ± 0.02

0.655

0.102

0.089

Group 4
(mean ± SD)

BMC

2.26 ± 0.11

2.73 ± 0.09

3.10 ± 0.16

0.068

0.068

0.021*

BMD

0.30 ± 0.02

0.31 ± 0.01

0.35 ± 0.02

0.180

0.068

0.017*

*P ˂ 0.05, significant difference between two groups.
P0-28 and P0-56, Wilcoxon test; P28-56, Mann–Whitney U test.
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bone formation. For this purpose, new methods aimed at
bone engineering and tissue regeneration are investigated.
Tissue engineering applications are used to provide bone
regeneration and cell proliferation in regions of bone
loss. Tissue engineering, unlike traditional biomaterial
applications, aims not only at the filling of the defect
regions of the lost tissues but also the formation of the
tissue having regeneration capacity (3,4).
Animal experiments are carried out mostly in dogs,
rabbits, mice, pigs, and hamsters because the tissue
structure of these animals is similar to that of humans.
Rats are used in research because of easy availability,
low cost, and the ease of obtaining tissue samples (13).
For these reasons, we did our work on rats. There is no
complete consensus on the size of the critical bone defect.
While many authors accepted the critical bone defect size
as 8 mm, others defined 4, 5, and 6 mm (14,15). In our
study, a 7-mm critically sized bone defect was created.
The second phase of bone healing, the granulation
phase, takes 7–12 days structurally. Granulation tissue
formed after this phase slowly transforms into soft fibrous
tissue. The soft callus formed during this process forms a
harder callus by the precipitation of Ca and P salts. Callus
formation occurs between 4 and 16 weeks (16,17). In our
study, the euthanasia days of the experimental animals
were determined by considering the bone healing rate
and by reference to similar studies in the literature. Many
organic, semisynthetic, fully synthetic, and alloplastic graft
materials were used in order to improve the bone tissue
with various losses of material due to different reasons
(18). The duration and rate of resorption are important in
bone graft materials. Early resorption may result in failure
to achieve the desired bone regeneration in bone tissue.
In recent years, research has focused on alloplastic grafts.
Among these grafts, β-TCP is a type of graft with late
resorption features that preserves its physical structure for
a long time in the defect area. Sometimes this resorption
period lasts for 1–1.5 years (19).
β-TCP provides a very strong osteoconductive effect
by providing intercellular communication between the
osteogenic cells that remain in the lacunas, whereas β-TCP
itself is very fragile. The skeletal structure is not resistant to
strong mechanical forces (8). When condensing this graft
at the defect site, excessive force should be avoided because
changes in the physical geometry of β-TCP and structural
breaks can occur. Although the pore size of β-TCP varies
between 1 and 1000 µm, the ideal pore size is between 50
and 150 µm (20). The size of the β-TCP graft pore used in
our study is between 25 and 100 µm.
Goshima et al. (21) formed a segmental bone defect
in rabbit tibia, and at week 4, they observed that the
granulation tissue began to mineralize and that osteoclasts
appeared. In the 6th and 8th week of the study, they found

that some of the graft particles began to be resorbed and
new bone islets were formed. In our study, inflammatory
cell infiltration and vascular dilatation and hemorrhage in
the β-TCP group of the non-diabetic rats on day 28 were
significantly lower than in the control group.
Ağacayak et al. (19) studied the effect of mesenchymal
stem cells in critically sized bone defects and reported
that very little osteoblastic activity occurred in the second
week compared to that rate in the 8th week. Similar to this
study, we found osteoblastic activity to be significantly
higher in the β-TCP group than in the control group
when comparing the histologic scores of the 56th day
of nondiabetic rats. According to these results, existing
osteoblastic activity on both the 28th day and the 56th day
in β-TCP groups indicates that bone healing is continuing
and defect filling occurs.
Chawla et al. (22) evaluated the β-TCP effect in 12
patients with a periodontal bilateral bone defect and
reported that the defect filling was significantly higher in
the β-TCP group compared to the control group.
Rojbani et al. (23) evaluated the osteoconductive effect
of the combination of simvastatin, HA, β-TCP, and α-TCP
in calvarial defects of rats; after 6 and 8 weeks, the new
bone formation with β-TCP and α-TCP was higher in the
samples.
Similar to the above studies, new bone formation was
found to be significantly higher in the β-TCP group than in
the control group when histological scores for days 28 and
56 of nondiabetic rats were compared. Thus, the evidence
of significant increases in new bone formation after the 4th
week in most of the studies performed with β-TCP grafts
are consistent with the study of Rojbani et al. (23).
ABS is a plant-based hemostatic agent derived from
Thymus vulgaris, Glycyrrhiza glabra, Vitis vinifera, Alpinia
officinarum, and Urtica dioica, approved by the Ministry
of Health of the Republic of Turkey on 26 October 2007.
All of these plants show their effects on the endothelium,
blood cells, angiogenesis, cellular proliferation, vascular
dynamics, and mediators. There are many studies
reporting that ABS can be used as a hemostatic agent
to control hemorrhage after dental extraction, surgical
operation, subgingival curettage, and periodontal plastic
surgery (24–26). Studies have also been conducted on the
effect of ABS on bone and soft tissue wound healing (26).
ABS has been reported to have a positive effect on new
bone formation in the wound healing process (25).
İşler et al. (12) investigated the effects of ABS on early
bone healing and fewer infections, less inflammation, and
less necrosis was detected in the defect group with ABS
while more new bone formation was reported. In our study,
rates of inflammatory cell infiltration, vascular dilatation,
and hemorrhage of nondiabetic rats were examined
on day 28, when the histological scores of the groups
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were compared. There was a significant decrease in the
ABS group compared to the control group. A significant
difference between the ABS group and the control group is
consistent with the results of this study.
In a study of the late effects of ABS on bone surfaces,
histopathological examination revealed that ABS
accelerated early bone healing and did not cause any
foreign body reactions (24).
In one study, the effect of ABS and heterologous bone
graft on bone healing was evaluated with sinus floor
augmentation applications of bone graft; there was no
evidence that a new bone formation occurred in any group
at week 1, but there was an increase in the formation of
new bone in all groups during the other weeks and the
maximum increase was observed in the ABS + heterograft
group, with the results reported as similar in all groups
at week 8 (27). In our study, the histological scores of
the nondiabetic rats on the 28th day were compared,
and although no statistically significant difference was
found between the ABS and β-TCP + ABS groups, new
bone formation was significantly higher in the β-TCP +
ABS group than in the control group. This study is also
consistent with the effect of β-TCP on the 56th day. A
significant difference between the β-TCP + ABS group
and the control group is consistent with the results of this
study.
In our study, we found a significant difference between
the ABS and control group when the histological scores of
nondiabetic rats on day 56 were compared. A statistically
significant difference between the ABS and control groups
indicates that ABS is effective both in early and late bone
healing. This is not consistent with the studies of Şimşek
et al. (24) and Günay et al. (28). In our study, histologic
scores of nondiabetic rats on day 56 were compared. The
new bone formation was found to be significantly higher
in the ABS and β-TCP + ABS groups than in the control
group. The ABS and β-TCP + ABS groups were found to
be significantly higher among themselves. Based on these
results, it was found that the β-TCP grafts had a positive
effect on bone regeneration on the 56th day alone and in
combination with ABS, and the highest efficacy was with
ABS.
Osteopontin is a major sialoprotein of the extracellular
bone matrix obtained from animal bone for the first
time. It has high affinity for hydroxyapatite, found in the
bone structure, and is a bone protein that acts as a bridge
between hydroxyapatite and cells (29). It is released from
many tissue cells, such as bone, dentin, semen, kidney,
fibroblasts in embryonic stroma, and wound healing areas
(30). Osteonectin, an extracellular matrix glycoprotein
with noncollagenous acidic properties, is synthesized by
osteoblasts in the bone matrix. It is found in periodontal
ligament, semen, bone, fibroblast, and osteoblast cells (31).
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In mineralization, proteoglycans and osteonectin provide
the release of calcium salts on collagen fibers because
osteonectin shows high affinity in binding calcium salts
(32).
We used the western blot method for serologic
methods, which showed more reliable results to eliminate
positively or negatively subjective evaluation of osteonectin
and osteopontin expressions that resulted from our
immunohistochemical staining method. More specific
protein bands are formed by the western blot method.
Thus, it enabled us to detect only certain proteins precisely
among a large number of proteins. In our study, we found
an increase in osteopontin and osteonectin expressions
of nondiabetic rats at day 28. The increase in osteopontin
expression is compatible with the findings of Nagata et al.
(33) and Thorwarth et al. (34). In our study, the western
blot method was used to determine which groups had
a significant increase in osteopontin and osteonectin
expressions. Osteopontin and osteonectin expressions
were found to be significantly higher in the β-TCP
and β-TCP +ABS groups on day 28. The expression of
osteopontin and osteonectin expression were significantly
higher in these two groups, indicating that osteoblast cells
and osteocytes were observed intensively. The presence
of cells that are effective in making bones in these groups
indicates that there is bone formation in these defects.
In our study, there was an increase in osteopontin and
osteonectin expressions in nondiabetic rats on day 56. The
present study is compatible with that of Agacayak et al.
(19). However, osteopontin and osteonectin expressions
were found to be not significant in any group by the
western blotting carried out to determine which groups
had increased expression. The osteopontin and osteonectin
expressions were higher in the early period, and there was
no increase in the late period, which may be due to the
osteoblastic activity being more intense in the early period.
DEXA measures the bone mineral density and amount
through the absorption of photons at different energy levels
(35). Today, it is still used as a gold standard. Scans are twodimensional and are used to determine the area density.
Barou et al. (36) examined bone loss and changes in rats
with osteoporosis using high-resolution three-dimensional
microcomputer tomography (3D-µCT), DEXA, and
histomorphometry. DEXA and 3D-µCT detected bone
loss changes on day 13 earlier than histomorphometry.
In another study where the density of bone trabeculae
in rats was measured by DEXA, histomorphometry, and
computed tomography (CT), DEXA and CT were found
significantly different from histomorphometry because
DEXA and CT measure cortical and cancellous bone,
whereas histomorphometry measures only cancellous
bone (35). For this reason, in our study, DEXA was used to
evaluate both early cortical and cancellous bone healing.
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Fındık et al. (35) investigated the effect of low-intensity
ultrasound waves on autogenous bone graft healing;
through DEXA analysis in 18 days, there was a significant
difference between groups for BMC and BMD values.
Reikeras et al. (37) investigated the effect of soft tissue on
the healing of tibial fractures in rats and DEXA analysis
on day 56 showed that there was no significant difference
between BMC and BMD values between groups in fracture
healing. BMD values of
 nondiabetic rats in our study are
in agreement with the findings of Reikeras et al. (37) and
are incompatible with the findings of Fındık et al. (35). The
fact that the findings of our study are inconsistent with the
findings of Fındık et al. (35) suggests that there may be an
increase in bone density due to the early resorption of the
autogenous bone used by Fındık et al. (35). In the present
study, BMD values were found to be low due to the long
resorption time of the alloplastic graft material.
BMC values of the nondiabetic rats on day 28 were
found significantly different between the control group
and the β-TCP and β-TCP + ABS groups, and also between
the β-TCP group and ABS and the ABS group and β-TCP
+ ABS. According to the findings of this study, the β-TCP
graft and ABS increase the amount of bone on day 28
radiologically; however, the β-TCP graft is more effective
in bone regeneration. The effects of β-TCP + ABS and
β-TCP graft on bone regeneration were found to be similar.
When BMC values of the nondiabetic group on day 56
were evaluated, the β-TCP group’s value was significantly

higher than that of the ABS group. In the same way, there
was a significant difference between the ABS group and the
β-TCP + ABS group. In this study, it was found that β-TCP
grafts on day 56 radiologically increased the amount of
bone more than ABS but in similar amounts with β-TCP
+ ABS. There was no significant difference in BMD values
between groups on the 28th and 56th days. Yuan et al. (8)
reported that there was a difference between the control
group and the β-TCP graft group when comparing the
BMD values between groups at week 32. In our study,
the planned 8-week duration was less in terms of BMD
change, so no significant results were found. In general,
there is no significant difference between BMD values in
short-term studies in the literature.
There was no significant difference in the nondiabetic
rats’ BMC and BMD values up to the 28th day and up to the
56th day. This may be due to the fact that the period of the
study was not long enough and due to the late resorption
of the synthetic graft material we used. It may also be due
to the material composition of β-TCP, pore size, geometry,
and particle structure.
In conclusion, this study presents research on the
combined use of a synthetic bone graft and ABS in bone
regeneration in nondiabetic rats. We believe that although
ABS suggests favorable wound healing and new bone
formation in nondiabetic rats, using it together with a
bone graft in cases where full bone regeneration is desired
will lead to more successful results.
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